NCT02720926 - Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Colorectal CancerGastric Cancer

Interventions

DRUG

Xeloda,

Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 day 1 every 21days

DRUG

TKI258

4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;

Trial Locations (1)

National Cancer Centre singapore, Singapore